Home
overview

More than 146 million adults in developed markets suffer from arthritis or related rheumatic conditions. Existing therapies have failed to meet the overwhelming market demand, and the pharmaceutical industry is heavily invested in the search of effective treatments to these chronic conditions
    
SMi's 7th Annual Anti-Arthritic Agents Conference offers a unique opportunity to hear about the latest developments from industry leaders. 
      
Examine the latest developments in the research of therapeutics for Arthritic and Inflammatory indications, and listen to case studies from the leading companies in the field. Discussions will include novel therapeutics, new approaches and technologies and will look into product differentiation and extended efficacy to meet the demands of the market:  
  • The search for novel chemical agents for treatment of rheumatic diseases
  • Advancement on bone biomarkers and skeletal damage in rheumatoid arthritis
  • Recent pharmaceutical research on  pain mechanisms for arthritic diseases
  • Seeking greater efficacy in existing treatments   
       
Bringing together knowledge and expertise, it’s designed to create the perfect setting for the exchange of ideas and networking opportunities.
      

Confirmed speakers include:
  • Dr Stephen Myers, Medical Director, Musculoskeletal Programmes, Eli Lilly
  • Dr Amanda Proudfoot, Director External Collaborations, Merck Serono
  • Dr Wolfgang Albrecht, Chief Scientific Officer, C-A-I-R Bioscience
  • Dr Andrew Salzman, Chief Executive Officer, Inotek Pharmaceuticals
  • Prof Gabriel Panayi, Rheumatology, Kings College London
  • Dr Alison Kerr, Managing Director, Inflammations Discovery Services, MD Biosciences


This conference is aimed at: 

  • Medical Directors
  • Director of Rheumatology
  • Senior Scientists - Arthritis and Inflammation Research
  • Directors of Clinical Research
  • Senior Clinical Project Managers


PLUS A HALF DAY CONFERENCE EXECUTIVE BRIEFING:

Refinement of Biological Therapies for Inflammatory Diseases

                                                                                                                

For Speaking opportunities please contact Mamta Patel at mpatel@smi-online.co.uk
For Sponsorship opportunities please contact Alia Malick at amalick@smi-online.co.uk

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Nigel Boughton-Smith

Dr Nigel Boughton-Smith, Principal Scientist Discovery & Emerging Products, Discovery Bioscience, AstraZeneca

9:10 EMERGING NEW BIOLOGIC THERAPIES: DRIVING FUTURE THERAPEUTIC STRATEGIES

Dr Brian Wong

Dr Brian Wong, Director, Rheumatology Discovery, Inflammation Disease Biology Area , Roche

  • The surge in biotherapeutics  - locating the un-met need
  • The search for steroid-action in chemical compounds
  • 9:50 THE CHEMOKINE SYSTEM PROVIDES MULTI-FACETED STRATEGIES FOR INFLAMMATORY DISEASES

    Dr Amanda Proudfoot

    Dr Amanda Proudfoot, Director, External Collaborations, Merck-Serono

  • Current status of development of oral small molecule receptor antagonists
  • Biological strategies
  • Can we learn from nature?
  • 10:30 Morning Coffee

    11:00 SMALL MOLECULE INHIBITORS OF T CELL COSTIMULATION VIA CD80 BLOCKADE

    Dr Neill Mackenzie

    Dr Neill Mackenzie, Senior Vice President, MediGene

  • Small molecule inhibitors of T cell costimulation via CD80 blockade
  • Novel, orally available compounds for inflammatory disease
  • Challenges of developing human-specific molecules
  • Preclinical models in RA and Psoriasis
  • 11:40 IMPROVED PRE-CLINICAL MODELS OF RHEUMATOID ARTHRITIS WITH CLINICALLY RELEVANT PATHOLOGY

    Dr Alison Kerr

    Dr Alison Kerr, Managing Director, Inflammations Discovery Services, MD Biosciences

  • Shortfalls of current pre-clinical models
  • Rapid pre-clinical models that maintain joint pathology
  • Relevant pre-clinical models
  • 12:20 Networking Lunch

    13:50 IKK2 INHIBITION IN PRECLINICAL MODELS OF RHEUMATOID ARTHRITIS

    Dr Elena Izmailova

    Dr Elena Izmailova, Senior Scientist, Millennium Pharmaceuticals

  • The need for mechanism based evidence for development of new therapeutics
  • IKK2 as a novel target
  • Biomarkers of IKK2 inhibition in arthritic models
  • 14:30 NOVEL CHEMICAL THERAPEUTIC AGENTS FOR TREATMENT OF RHEUMATIC DISEASES

    Dr Wolfgang Albrecht

    Dr Wolfgang Albrecht, Chief Scientific Officer, C-A-I-R Bioscience

  • Current status of development of protein kinase inhibitors for treatment of autoimmune diseases
  • Multiple activation mechanisms of protein kinases as a major hurdle for clinical development of small molecules?
  • Protein kinase phosphatases as alternative targets
  • Outlook compared to available and emerging biological therapies
  • 15:10 Afternoon Tea

    15:40 BIP-INDUCED REGULATORY CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    Prof Gabriel Panayi

    Prof Gabriel Panayi, ARC Professor, Rhuematology, Department of Rheumatology, Kings College London

    • BiP is an ER chaperone found in extra-cellular fluids
    • In humans BiP will:
    • o        Induce anti-inflammatory phenotype in human monocytes
      o        BiP-specific T-cell clones secrete TH2 cytokine
      o        Suppress T-cell proliferative responses
      • In Mice BiP will:
      • o        Prevent and treat CIA
        o        Induce regulatory cells
        o        Regulatory cells suppress CIA
        o        IL-4 necessary for induction/action BiP
        • BiP suppresses inflammation in RA SM tissue transplanted into SCID mice
        • ·         BiP potential new immunomodulator for RA

    16:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Rizgar Mageed

    Rizgar Mageed, Professor, Experimental Immunology, Bone Joint Research, The William Harvey Research Institute

    9:10 OPPORTUNITIES FOR BONE ANABOLIC THERAPIES IN THE TREATMENT OF ARTHRITIS

    Dr Adrian Moore

    Dr Adrian Moore, Senior Group Leader, Pharmacology, UCB-Celltech

    9:50 RECENT TRENDS AND CHANGES IN THE DEAL MAKING ENVIRONMENT FOR ANTI-ARTHRITIS PRODUCTS

    John  Janes

    John Janes, Managing Consultant, PharmaVentures

  • A comparison of the environment for biologics and RA products
  • Deal values and structures: co development and co promotion clauses
  • The future competitive environment
  • 10:30 Morning Coffee

    11:00 BONE BIOMARKERS AND SKELETAL DAMAGE IN RHEUMATOID ARTHRITIS

    Dr Stephen Myers

    Dr Stephen Myers, Medical Director, Musculoskeletal Programs, Eli Lilly & Co

  • Using bone formation and resorption markers in clinical trials
  • Disease-related changes in cortical and trabecular bone
  • Therapeutic opportunities in the damaged skeleton
  • 11:40 INTEGRATION OF KINETICS, SAFETY AND EFFICACY EVALUATION IN PRECLINICAL ARTHRITIS STUDIES

    Anne-Marie Zuurmond

    Anne-Marie Zuurmond, Project Manager, TNO Pharma

  • (Limitations of) Existing in vitro and in vivo efficacy assays
  • Combining kinetics, safety and efficacy evaluation
  • 12:20 Networking Lunch

    13:50 MRI Assessment of Rheumatoid Arthritis

    Stephen Oakley

    Stephen Oakley, Professor of Rheumatology, Ixico

    • Novels compounds for the prevention of arterial thrombosis
    • Blocking the formation of blood clots mediated through inflammation without increasing bleeding risk
    • Biomarker development

    14:30 COMPOUND AND BIOLOGICS EVALUATION IN ANIMAL MODELS OF RHEUMATOID ARTHRITIS

    Dr Simon  Cruwys

    Dr Simon Cruwys, Team Leader, Research and Development, Respiratory and Inflammation, AstraZeneca

    15:10 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Refinement of Biological Therapies for Inflammatory Diseases
    Workshop

    Refinement of Biological Therapies for Inflammatory Diseases

    Hesperia Victoria Hotel
    21st November 2007
    London, United Kingdom

    Hesperia Victoria Hotel

    2 Bridge Place
    Victoria
    London SW1V 1QA
    United Kingdom

    Hesperia Victoria Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.